✦ LIBER ✦

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

✍ Scribed by Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò

Book ID: 119609109
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 336 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70489-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib as maintenance treatment in ad

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

✍ Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Aleksandra S 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 321 KB

Docetaxel plus nintedanib versus docetax

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

✍ Reck, Martin; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Se 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 382 KB

Gefitinib plus best supportive care in p

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

✍ Thatcher, Nick (author);Chang, Alex (author);Parikh, Purvish (author);Rodrigues 📂 Article 📅 2005 🏛 Elsevier BV 🌐 English ⚖ 158 KB

Irinotecan plus gemcitabine vs irinoteca

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

✍ Georgoulias, V; Kouroussis, C; Agelidou, A; Boukovinas, I; Palamidas, P; Stavrin 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Vinorelbine plus gemcitabine followed by

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study

✍ Kaoru Kubota; Masaaki Kawahara; Mitsumasa Ogawara; Yutaka Nishiwaki; Kiyoshi Kom 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 173 KB

Ramucirumab plus docetaxel versus placeb

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

✍ Garon, Edward B (author);Ciuleanu, Tudor-Eliade (author);Arrieta, Oscar (author) 📂 Article 📅 2014 🏛 Elsevier BV 🌐 English ⚖ 389 KB